benazepril / Generic mfg. - LARVOL DELTA

New drugs for small animals in 2025 (PubMed, Tierarztl Prax Ausg K Kleintiere Heimtiere) - "In 2025, 3 novel pharmaceutical agents for small animals were released on the German veterinary medicinal products market: the 2 Janus kinase inhibitors atinvicitinib and ilunocitinib for the treatment of pruritus associated with allergic or atopic dermatitis, and the serotonin reuptake inhibitor fluoxetine for the adjunctive treatment of separation-related behavioral disorders. New to the market for small animals are: 2 active substances (benazepril, pimobendan), each with a new dosage form; one active substance (meloxicam) with a new dosage form and content of active substance; 3 active substances (enflicoxib, milbemycin oxime+praziquantel, tramadol) with new content of active substance, a new combination of active substances (terbinafine+betamethasone acetate), and 2 active substances (metoclopramide, mirtazapine) with new package sizes. There were no new vaccines for small animals in 2025."

Journal • Atopic Dermatitis • Behavior Disorders • Dermatitis • Dermatology • Immunology • Mental Retardation • Pruritus • Psychiatry

Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs. (PubMed, J Vet Intern Med) - "In this experimental model of RAAS activation, benazepril/spironolactone combination therapy exerts effects on markers of inflammation and fibrosis in dogs."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • MMP10 • TSLP

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis. (PubMed, Front Cardiovasc Med) - "S/V showed superior efficacy in improving short-term cardiac systolic function, as measured by surrogate echocardiographic endpoints. These preliminary findings require validation in larger, prospective randomized controlled trials with longer follow-up to confirm whether these benefits translate into improved long-term clinical outcomes."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Antihypertensive and anti-ischemic effects of diltiazem in patients with primary hypertension. (PubMed, Medicine (Baltimore)) - "Patients were assigned to 1 of 4 treatment groups: benazepril monotherapy group (benazepril 10 mg/day, n = 44); irbesartan monotherapy group (irbesartan 150 mg/day, n = 45); diltiazem monotherapy group (diltiazem hydrochloride sustained-release tablets 90 mg/day, n = 36); and combination therapy group (diltiazem hydrochloride sustained-release tablets 90 mg/day plus either benazepril 10 mg/day or irbesartan 150 mg/day, n = 35). Combination therapy with diltiazem and other antihypertensive agents, particularly benazepril, may offer additional therapeutic benefits. These findings support the potential role of diltiazem in the management of patients with mild to moderate hypertension and subclinical myocardial ischemia."

Journal • Observational data • Cardiovascular • CNS Disorders • Depression • Hypertension • Myocardial Ischemia • Psychiatry

Serum peptidomic profiling and peptide mass fingerprinting reveal signatures associated with peroxisomal and mitochondrial pathways in MMVD-associated cardiorenal syndrome in dogs. (PubMed, PLoS One) - "These proteins are associated with the arginine and proline metabolism and peroxisome pathways, which were found to be influenced by standard medications such as pimobendan, furosemide, spironolactone, benazepril, and sildenafil. The convergence of peroxisomal and mitochondrial dysfunction suggests a unifying mechanism for parallel cardiac and renal deterioration. These proteomic markers persist despite standard medical therapy, highlighting their potential as auxiliary tools for risk stratification and the monitoring of treatment efficacy in canine cardiorenal syndrome."

Biomarker • Journal • Cardiovascular • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease • GLRX

Adverse event of ACE inhibitors: A descriptive analysis of FAERS data. (PubMed, J Public Health Res) - "This retrospective pharmacovigilance study analyzed FAERS reports submitted from January 1, 1979, through March 31, 2025, for nine ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, and trandolapril) identified as primary suspect drugs. Adults and elderly patients carry the highest burden of ADEs, though pediatric cases remain clinically relevant for specific agents. These findings support tailored monitoring and risk mitigation strategies in clinical practice."

Adverse events • Journal • Acute Kidney Injury • Cardiovascular • Cough • Hypertension • Hypotension • Nephrology • Pediatrics • Renal Disease • Respiratory Diseases

Cost effective industrial scale synthesis of bromo-benzo[b]azepinone: an intermediate for benazepril. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This optimized synthetic route for 3-bromo-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one is efficient, scalable, and environmentally sustainable. By integrating step telescoping with greener reagents, the process meets industrial pharmaceutical manufacturing goals, offering both economic advantages and environmental benefits in Benazepril production."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD) (clinicaltrials.gov) - P4 | N=64 | Active, not recruiting | Sponsor: Baylor Research Institute

New P4 trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Environmental sustainability assessment of reverse-phase liquid chromatography for retention and ionization profiling of angiotensin-converting enzyme inhibitors. (PubMed, J Pharm Biomed Anal) - "This paper presents a sustainable chromatographic framework using reverse-phase liquid chromatography (RPLC) method with an ultraviolet detector (UV) to determine the ionization behavior of three angiotensin-converting enzyme (ACE) inhibitors, benazepril, cilazapril, and quinapril, in a water-organic solvent binary mixture...The values calculated from these studies are compatible with each other and with the literature values. The dependence of the developed methods on twelve green analytical chemistry (GAC) principles was evaluated using the Analytical Greenness Metric (AGREE score=0.77), the Green Analytical Procedure Index (GAPI), and the Analytical Green Star Area (AGSA score=90.28)."

Journal

APPLICATION OF TRF-BUDESONIDE (NEFECON) IN THE TREATMENT OF PEDIATRIC PATIENT WITH IGA NEPHROPATHY: A CASE REPORT (ISN-WCN 2026) - "Introduction Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerular diseases in children and adolescents, with 20% of affected children progressing to end-stage kidney disease (ESKD) within 20 years of diagnosis. A 6-month follow-up confirmed sustained benefits with Benazepril alone. These findings suggest Nefecon may be a safe and effective option for pediatric IgAN, but further large-scale studies are needed to confirm long-term safety, optimal dosing, and efficacy across diverse pediatric populations."

Case report • Clinical • Acne Vulgaris • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Human Immunodeficiency Virus • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pediatrics • Renal Disease

Treatment of glomerular and tubular proteinuria in the nephrotic range in a female cat: case report. (PubMed, Braz J Vet Med) - "Treatment included furosemide, dexamethasone, benazepril, omega-3 fatty acid, mirtazapine and renal diet, in addition to procedures such as paracentesis for drainage. The patient remained stable, with no recurrence of symptoms. The therapeutic conclusions are limited by the single-case design, although continuous clinical and laboratory monitoring was implemented, aiming to adjust therapeutic management."

Journal • Glomerulonephritis • Nephrology • Pulmonary Disease • Renal Disease

Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (clinicaltrials.gov) - P2 | N=50 | Completed | Sponsor: Shanghai Children's Hospital | Recruiting ➔ Completed

Trial completion • Genetic Disorders • COL4A5

Effect of sacubitril/valsartan and ACEI/ARB on left ventricular remodeling in patients with STEMI after PCI: a prospective, superiority randomized controlled trial (ChiCTR) - P=N/A | N=76 | Not yet recruiting | Sponsor: General Hospital of the Northern Theater Command, People's Liberation Army, No.83 Wenhua Road, Shenhe District, Shenyang City, Liaoning Province; Gene

New trial

Cilazapril and benazepril mitigate neurodegeneration and α-synuclein accumulation in a cellular model of parkinson's disease. (PubMed, Sci Rep) - "They modulated genetic pathways involved in dopaminergic signalling and showed high binding affinity for the AT1, AT2, D1A, D1B and D2 receptors. These findings suggest that cilazapril and benazepril exert multi-targeted protective effects that extend beyond simple antioxidant activity, and that they may be effective in treating or mitigating PD-related neurodegeneration."

Journal • CNS Disorders • Inflammation • Movement Disorders • Neuroblastoma • Oncology • Parkinson's Disease • Solid Tumor • IL10 • IL1B • TGFB1 • TNFA

The cost divide: Why veterinary medicinal products for dogs and cats in the EU cost more than their human equivalents. (PubMed, Res Vet Sci) - "Using comparative data on furosemide, amoxicillin, benazepril, and prednisone, the paper identifies how lack of public price negotiation, high VAT rates, concentrated market structure, and limitations in pet insurance coverage contribute to affordability challenges. The findings provide policy-relevant insights into how the EU could better align VMP pricing with principles of accessibility, sustainability, and innovation."

Journal

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets and Sacubitril Alisartan Calcium Tablets Combined with Amlodipine Besylate Tablets (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Guangzhou Medical University; The Second Affiliated Hospital of Guangzhou Medical University

New trial • Cardiovascular • Hypertension

Efficacy and safety of Ambrisentan on idiopathic membranous nephropathy----a prospective, multi-center, randomized and controlled study (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Army Medical University; Army Medical University

New trial • Glomerulonephritis • Renal Disease

Spectroscopic investigation of the competitive-allosteric-synergistic mechanism in the binding of benazepril/apigenin to bovine serum albumin. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Additionally, free sulfhydryl group (SH) assays indicated that both AP and BNZ protect free SH, with AP being the dominant factor. Esterase activity experiments confirmed that AP and BNZ synergistically inhibit BSA function."

Journal

Comparative Study on the Neuroprotective Effects of Perindopril and Benazepril in Experimentally-induced Chronic Mild Stress in Rats. (PubMed, J Neuroimmune Pharmacol) - "This study is among the first to highlight the antidepressant potential of benazepril, a non-centrally acting ACE inhibitor, and provides novel insights into its comparative efficacy against perindopril. These results collectively emphasize the broader therapeutic potential of ACE inhibitors in treating depression and underscore the need for further research to fully explore their underlying mechanisms and diverse applications in psychiatric disorders."

Clinical • Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mental Retardation • Mood Disorders • Psychiatry

Centrally Acting ACE Inhibition in SLE (clinicaltrials.gov) - P2 | N=36 | Active, not recruiting | Sponsor: Northwell Health | Trial completion date: Nov 2025 ➔ Mar 2026

Trial completion date • Cognitive Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Comparison of the effects of dual, triple, and quadruple medical therapy on cardiac death in a retrospective cohort of dogs with myxomatous mitral valve disease at American College of Veterinary Internal Medicine stage C: is more necessarily better? (PubMed, J Am Vet Med Assoc) - "To compare selected cardiac effects of dual therapy (DT; furosemide and pimobendan), triple therapy (TT; furosemide, pimobendan, and benazepril), and quadruple therapy (QT; furosemide, pimobendan, benazepril, and spironolactone) in dogs with myxomatous mitral valve disease at American College of Veterinary Internal Medicine (ACVIM) stage C. This was a multicenter retrospective study involving dogs with ACVIM stage C myxomatous mitral valve disease treated with DT, TT, or QT. In this study sample, QT and TT did not provide a higher clinically evident cardiac protective effect compared to DT. DT was not inferior to TT and QT in terms of cardiac death in dogs with ACVIM stage C myxomatous mitral valve disease included in this study."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Safety of Drugs in Breastfeeding Women With CKD. (PubMed, Kidney Int Rep) - "Among renin-angiotensin system inhibitors, enalapril and captopril are safe for breastfeeding. Based on limited evidence, quinapril, benazepril, candesartan, and valsartan are likely acceptable for use during breastfeeding. We found no compelling human data regarding the safety of other renin-angiotensin system inhibitors or sodium-glucose cotransporter type 2 (SGLT2) inhibitors, finerenone, sparsentan, or glucagon-like peptide-1 receptor agonists (GLP1RAs) in lactation. Immunosuppressive agents, including azathioprine, cyclosporine, tacrolimus, budesonide, rituximab, and eculizumab are acceptable for use during breastfeeding. Belimumab is most likely safe; however, data are limited...No studies were found on the safety of breastfeeding while on the newer complement inhibitors, including avacopan, ravulizumab, iptacopan, and pegcetacoplan...Human lactation data on the safety of most drugs used in the treatment of CKD are limited, making evidence-based recommendations..."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Jianpi Qushi Heluo Formula ameliorates podocytes injury related with ROS-mediated NLRP3 inflammasome activation in membranous nephropathy by promoting PINK1-dependent mitophagy. (PubMed, J Ethnopharmacol) - "JQHF can alleviate podocyte damage, that through inhibiting ROS-mediated NLRP3 inflammasome activation by improving PINK1-mediated mitophagy."

Journal • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease • IL1B • IL6 • NLRP3 • NPHS1 • PINK1

Multiomics genetic insights into potential molecular targets for intracranial aneurysm. (PubMed, Stroke Vasc Neurol) - "The study identified key targets for aSAH and uIA, providing insights for developing preventive therapies and advancing research on intracranial aneurysm mechanisms."

Journal • Cardiovascular • Inflammation • Subarachnoid Hemorrhage • Vascular Neurology • PRCP • TNFSF12

The effect of Zuogui-Jiangtang-Yishen decoction on the intestinal flora's response to L-α-phosphatidylcholine and L-tyrosine in patients with diabetic kidney disease: an in vitro study. (PubMed, Front Pharmacol) - "Our previous clinical research also showed that ZGJTYS prevents DKD in a manner similar to that of benazepril...ZGJTYS was found to effectively restore the microbiota that were altered by L-α-phosphatidylcholine and L-tyrosine to normal, along with their metabolites. However, the mechanism by which ZGJTYS exerts its preventive and therapeutic effects on DKD through the gut microbiota still requires further study."

Journal • Preclinical • Diabetic Nephropathy • Nephrology • Renal Disease